Clinical Trial Update: Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of DCR-PHXC in Primary Hyperoxaluria Type 3 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• DCR-PHXC

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria Type 3 | Phase 1 | Status: COMPLETED